Clinical trials: Exudative Macular Degeneration
Exudative Macular Degeneration
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and…
- Trial name
- NCT05093374
- Testing
- anti-VEGF agent
- Where
- Austria
- Volunteers
- 290 people
- Sponsor
- Medical University of Vienna
Exudative Age-Related Macular Degeneration
A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
The primary objective of this proposed research study is to evaluate the safety of intravitreal ranibizumab in combination with intravitreal dexamethasone in comparison to intravitreal ranibizumab alone in the treatment of wet…
- Trial name
- Lucedex (NCT00793923)
- Testing
- ranibizumab and dexamethasone, Ranibizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Subhransu K. Ray, M.D., Ph.D.
Eye Diseases, Macular Degeneration, Wet
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces.
- Conditions
- Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage
- Trial name
- TIGER (NCT04663750)
- Testing
- Pars plana vitrectomy, Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until month 12, subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
- Where
- 42 sites in Germany, Ireland and 5 more
- Volunteers
- 210 people
- Sponsor
- King's College Hospital NHS Trust
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-Related Macular Degeneration (AMD), Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD
- Trial name
- NCT02348359
- Testing
- X-82, Anti-VEGF
- Where
- 35 sites in United States
- Volunteers
- 157 people
- Sponsor
- Tyrogenex
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-related Macular Degeneration, Detachment of the Posterior Hyaloid
Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD
Choroidal neovascularisation in age related macular degeneration is one of the major causes of legal blindness in the western world existing in two major occurences, the dry and the wet form.The etiology of age related macular…
- Trial name
- PAM (NCT00926861)
- Testing
- ultrasound, OCT
- Where
- Austria
- Volunteers
- 320 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Dry Age-related Macular Degeneration
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with Intermediate Non-Exudative Macular Degeneration
- Trial name
- NCT03626636
- Testing
- Risuteganib
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Allegro Ophthalmics, LLC
Neovascular Age-related Macular Degeneration
Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD
Double-masked, uncontrolled, multi-center, study in which participants will be randomized to one of 3 doses of topical ocular PAN 90806 administered once daily for 12 weeks.
- Trial name
- NCT03479372
- Testing
- PAN-90806 Ophthalmic Suspension
- Where
- 18 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- PanOptica, Inc.
Age-Related Macular Degeneration (AMD)
EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).
This prospective, observational, open-label study evaluates early treatment response to intravitreal aflibercept 8 mg in patients with exudative age-related macular degeneration.
- Trial name
- ELEV8 (NCT07434713)
- Testing
- treatment with Aflibercept 8mg (Eylea)
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of ranibizumab.
- Trial name
- CyPov (NCT02976194)
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Pusan National University Hospital
Choroidal Neovascularization, Wet Macular Degeneration
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
- Trial name
- DECO (NCT03452527)
- Testing
- ICON-1, aflibercept
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Iconic Therapeutics, Inc.
Macular Degeneration
Systemic Avastin Therapy in Age-Related Macular Degeneration
Choroidal neovascularisation (CNV) in age-related macular degeneration is one of the major causes of blindness in the western world.
- Trial name
- BEAT-AMD (NCT00531024)
- Testing
- Bevacizumab, Sodium Chloride
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Exudative Age-related Macular Degeneration
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
•Purpose: Age-related Macular Degeneration ( AMD) is the leading cause of blindness and visual impairment in industrialized countries.
- Trial name
- NCT01404845
- Testing
- Nutrof Total, food supplement without Lutein and Zeaxanthin
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Affordance
Age-Related Macular Degeneration
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration.
- Trial name
- NCT01174407
- Testing
- cd 35, cd21, cd55
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Rudolf Foundation Clinic
Exudative Age Related Macular Degeneration
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
The purpose of this trial is to detect the influence of omega-3 supplements on vitreous levels of vascular endothelial growth factor (VEGF) in exudative age-related macular degeneration (AMD) in patients receiving intravitreal…
- Trial name
- NCT01819415
- Testing
- Anti-VEGF plus AREDS-2, Anti-VEGF plus AREDS-1
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Macular Edema
Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3
To determine whether a combination of intravitreal aflibercept and pranoprofen eyedrops or nutraceutical support provides additional benefit over IVA monotherapy for the treatment of choroidal neovascularization in age-related…
- Trial name
- NCT03355638
- Testing
- Aflibercept Injection [Eylea], Pranoprofen Eyedrops, Omega-3 Supplementation
- Volunteers
- 60 people
- Sponsor
- Università degli Studi di Brescia
Macular Degeneration, Macular Degeneration, Wet
Prediction of Progression of Age-Related Macular Degeneration
The goal for this study is to initiate a randomized, controlled clinical trial to test the viability of personalized AMD progression prediction models.
- Conditions
- Macular Degeneration, Macular Degeneration, Wet, Macular Degeneration, Dry
- Trial name
- NCT04640649
- Testing
- Algorithm prediction
- Volunteers
- 278 people
- Sponsor
- University of Illinois at Chicago
Subretinal Hemorrhage and Exudative Maculopathy
Pneumatic Displacement of Subretinal Hemorrhage With Perfluorocarbon Gases
Subretinal hemorrhage in the macula causes a significant loss of vision. This hemorrhage can be displaced by the use of a small volume of pure perfluorocarbon gas injected into the vitreous, which expands to a 40% gas bubble in…
- Trial name
- NCT00161525
- Testing
- Pneumatic displacement
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Weill Medical College of Cornell University
Exudative Age-related Macular Degeneration
Ethical Issues of Using Gene Therapy in the Treatment of AMD
The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD).
- Trial name
- NCT07004361
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital